AI/ML Innovations Inc. Announces Late Filing of Annual Financial Disclosure

Rhea-AI Summary

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced a delay in filing its annual financial disclosure for the year ended April 30, 2024. The company has applied for a management cease trade order (MCTO) from the British Columbia Securities Commission to avoid a general cease trade order. The delay is due to the inability of bookkeepers from its investee, Tech2Heal, to provide necessary financial information for audit completion.

The company expects to file the required documents by September 15, 2024, missing the original August 28, 2024 deadline. During the MCTO period, if granted, only insiders will be restricted from trading the company's securities. AI/ML Innovations focuses on artificial intelligence and machine learning in digital health and wellbeing, with investments in Health Gauge, Tech2Heal, and AI Rx Inc.

Positive

• The company has proactively applied for an MCTO to maintain trading for non-insiders
• AI/ML Innovations has a diverse portfolio in AI and ML-driven digital health companies

Negative

• Delay in filing annual financial statements and related documents
• Potential for a general cease trade order if MCTO is not granted
• Dependence on external entity (Tech2Heal) for important financial information

VICTORIA, BC / ACCESSWIRE / August 23, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) announces that it has made an application to the British Columbia Securities Commission ("BCSC") to approve a management case trade order ("MCTO") under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"), which, if granted, will prohibit trading in the securities of the Company by the Chief Executive Officer and Chief Financial Officer of the Company until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the Company, will continue to be able to trade in the Company's listed securities. The MCTO application has been made but there is no guarantee or assurance that the MCTO will be granted. If the MCTO is not issued by the BCSC, the applicable Canadian securities regulatory authorities could issue a general cease trade order against the Company for failure to file the Required Filings within the prescribed time period.

The Company expects that it will be unable to file its audited financial statements for the financial year ended April 30, 2024, and the related management's discussion and analysis and Chief Executive Officer and Chief Financial Officer certificates for this period (collectively, the "Required Filings") before the filing deadline of August 28, 2024 (the "Filing Deadline").

The Company will be late in the preparation of the Annual Filings as a result of the bookkeepers for one of its investee entities (Tech2Heal) being unable to provide the Company with certain financial information that the Company's auditors need to complete their audit. Due to the Company's material investment in Tech2Heal, Tech2Heal was required to supply documentation to be audited by the Company's auditors to support incorporation into the Company's consolidated financial statements by way of equity accounting. The bookkeepers for Tech2Heal are located in France and due to extended holidays in that country over the summer the Company is not expected to receive the information that it needs until approximately September 1, 2024.

The Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or before September 15, 2024. The MCTO will be in effect until the Required Filings are filed. The Company intends to satisfy the provisions of the alternative information guidelines set out in sections 9 and 10 of NP 12-203 so long as the Required Filings are outstanding.

The Company confirms that there are no insolvency proceedings against it as of the date of this press release. The Company also confirms that there is no other material information concerning the affairs of the Company that has not been generally disclosed as of the date of this press release.

For more information about AI/ML Innovations:

For detailed information please see AI/ML's website or the Company's filed documents at www.sedar.com.

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

About AI/ML Innovations Inc. https://aiml-innovations.com/

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (22% ownership commitment by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

Certain statements in this news release are "forward-looking statements", which reflect management's expectations regarding the issuance of the MCTO and timing of the filing of the Required Filings. All statements other than statements of historical fact contained in this news release are forward-looking statements. Such forward-looking statements involve risks and uncertainties, as they reflect management's current beliefs and are based on information currently available to management. Actual results may differ materially from those anticipated in the statements made. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update or revise them to reflect new events or circumstances except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at www.sedar.com.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AI/ML Innovations, Inc.

View the original press release on accesswire.com

FAQ

Why is AI/ML Innovations (AIMLF) delaying its annual financial filing?

AI/ML Innovations is delaying its annual financial filing due to the inability of bookkeepers from its investee, Tech2Heal, to provide necessary financial information for audit completion. This delay is caused by extended summer holidays in France, where Tech2Heal's bookkeepers are located.

When does AI/ML Innovations (AIMLF) expect to file its delayed annual financial statements?

AI/ML Innovations anticipates filing its delayed annual financial statements and related documents by September 15, 2024, missing the original deadline of August 28, 2024.

What is the impact of the MCTO on AI/ML Innovations (AIMLF) stock trading?

If granted, the MCTO will only restrict insiders from trading AI/ML Innovations securities. The general public will still be able to trade the company's listed securities during the MCTO period.

What are the main business areas of AI/ML Innovations (AIMLF)?

AI/ML Innovations focuses on artificial intelligence (AI) and machine learning (ML) in digital health and wellbeing. The company has investments in Health Gauge, Tech2Heal, and AI Rx Inc., capitalizing on AI and ML applications in healthcare management solutions.